Skip to main content
. 2020 Dec 10;8(2):e001315. doi: 10.1136/jitc-2020-001315

Figure 2.

Figure 2

The association between EPHA mutation and clinical response to immune checkpoint inhibitors in China cohort. (A) Kaplan-Meier survival curves of progression-free survival (PFS) comparing the EPHAmut group and EPHAwt group in China cohort. (B) The ratio of patients with complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) treated with anti-PD-(L)1 antibody in EPHA mutation and EPHA wide-type group. *P<0.05 by Fisher’s exact test.